Avadel Pharmaceuticals
  • Recent News
  • Investors
  • About
    • Overview
    • Leadership
    • Board of Directors
    • Business Development
    • Corporate Responsibility
  • Research
    • Clinical Trials
  • Contact Us
  • Call Today
  • Email Us
  • Our Map
    • Avadel Pharmaceuticals
    • 636.449.1830
    • About
      • Overview
      • Leadership
      • Board of Directors
      • Business Development
      • Corporate Responsibility
    • Research
      • Clinical Trials
    • Contact Us
    • Investors
      Careers
636.449.1830

The first FDA-Approved neostigmine methylsulfate injection products offering proven efficacy.

Important Safety Information

INDICATIONS AND USAGE

BLOXIVERZ® (Neostigmine Methylsulfate Injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.

DOSAGE AND ADMINISTRATION

  • Should be administered by trained healthcare providers
  • Peripheral nerve stimulator and monitoring for twitch responses should be used to determine when BLOXIVERZ should be initiated and if additional doses are needed
  • For reversal of NMBAs with shorter half-lives, when first twitch response is substantially greater than 10% of baseline, or when a second twitch is present: 0.03 mg/kg by intravenous route
  • For reversal of NMBAs with longer half-lives or when first twitch response is close to 10% of baseline: 0.07 mg/kg by intravenous route
  • Maximum total dosage is 0.07 mg/kg or up to a total of 5 mg (whichever is less)
  • An anticholinergic agent, e.g., atropine sulfate or glycopyrrolate, should be administered prior to or concomitantly with BLOXIVERZ

CONTRAINDICATIONS

  • Hypersensitivity to neostigmine
  • Peritonitis or mechanical obstruction of the intestinal or urinary tract

WARNINGS AND PRECAUTIONS

  • Bradycardia: Atropine or glycopyrrolate should be administered prior to BLOXIVERZ to lessen risk of bradycardia.
  • Serious Reactions with Coexisting Conditions: Use with caution in patients with, coronary artery disease, cardiac arrhythmias, recent acute coronary syndrome or myasthenia gravis.
  • Neuromuscular Dysfunction: Can occur if large doses of BLOXIVERZ are administered when neuromuscular blockade is minimal; reduce dose if recovery from neuromuscular blockade is nearly complete.

ADVERSE REACTIONS

Most common adverse reactions during treatment: bradycardia, nausea, and vomiting.

To report SUSPECTED ADVERSE REACTIONS, contact Avadel at 1-877-638-4579 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

0118 BLX HCP ISI

View Prescribing Information

Products

  • Hospital
    • Bloxiverz ®
    • Vazculep ®
    • Akovaz ®

Contact Avadel Pharmaceuticals Today

Avadel Pharmaceuticals

Helpful Links Site Map | Privacy Policy | Terms and Conditions

  • Overview
  • News & Events
  • Careers
  • Investors
  • Contact Us
16640 Chesterfield Grove Road,
Suite 200,
Saint Louis, MO 63005 |  View Map [+]
https://www.avadel.com/
Site Map | Privacy Policy
http://www.avadel.com

© Avadel. All rights reserved.

0218 AVL WBST HSP PRDCTS BLX_BM3

Powered by Scorpion